Greater Glasgow and Clyde Medicines

The supply of GLP-1 RAs continues to be limited, with supply not expected to return to normal until at least the end of 2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications.

Guideline News February 2024 here

To access the full blog via Microsoft Sway, click here

Key Medicine Shortages February 2024 here

Includes:

GLP-1 Receptor Agonists, Lamotrigine 5mg dispersible tablets, Tresiba® (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens and Phenytoin sodium 100mg capsules (Accord)

Key messages

• Use of antifibrotic medicines (nintedanib (Ofev®), pirfenidone) is restricted to
  specialist initiation and use for the management of fibrotic Interstitial Lung Disease
  (ILD) and has to be approved by the ILD Multi-Disciplinary Team (MDT)
• Supply of these medicines and required monitoring is via the pharmacist led ILD
  medication service. Medication is supplied directly to patients via homecare
• Respiratory consultants can request initiation, titration and monitoring of
  immunosuppressant medications for ILD patients such as azathioprine, methotrexate,
  mycophenolate, prednisolone via this service. Clear communication will be made with
  primary care with regards to ongoing medication supply.
• The pharmacist ILD team can be contacted via email:
  ggc.interstiallungdisease@ggc.scot.nhs.uk, or by telephone on 07977 154764. This is staffed Monday to Friday and replies are normally within 24 hours.

Key Medicine Shortages January 2024 here

Includes:

Phosphate Sandoz® (sodium dihydrogen phosphate anhydrous 1.936g) effervescent tablets and Sando K® (potassium bicarbonate 400mg, potassium chloride 600mg) effervescent tablets